A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Autor: Alvaro Lassaletta, Joseph Rubino, Michael Nebozhyn, Kumudu Pathiraja, Zsuzanna Pápai, Brian Der-Hua Lu, Richard Gorlick, Darcy A. Hille, Najat C. Daw, Odd R. Monge, Keith M. Skubitz, Stefan S. Bielack, Cynthia E. Herzog, Mark Ayers, David J. Mauro, Erica Boldrini, Peter M. Anderson, Siu Long Yao

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Pediatric Blood & Cancer

Background Robatumumab (19D12; MK-7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin-like growth factor receptor-1 (IGF-1R). This multiinstitutional study (P04720) determined the safety and clinical effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ff23f29cb2e441ba8c22ae025c90df5
https://hdl.handle.net/20.500.12530/26021